Ngm Biopharmaceuticals Inc

-0.91 (-3.58%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)1.88B
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$22.49 Million
Adjusted EPS-$0.41
See more estimates
10-Day MA$26.63
50-Day MA$28.13
200-Day MA$22.76
See more pivots

NGM Biopharmaceuticals, Inc. Stock, NASDAQ:NGM

333 Oyster Point Boulevard, South San Francisco, California 94080-7014
United States of America
Phone: +1.650.243.5555
Number of Employees: 186


NGM Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutics for cardio-metabolic, liver, oncologic, and ophthalmic diseases. Its portfolio include aldafermin (NGM282), NGM313, NGM120, NGM217, NGM621, and NGM395. The company was founded by Jin-Long Chen in 2008 and is headquartered in South San Francisco, CA.